The bone mineral mass was estimated by photon absorptiometry in 23 epileptic patients on long-term treatment with phenytoin and in 20 normal subjects before and during treatment with vitamin D or placebo.
Introduction
Manifest biochemical osteomalacia (with hypocalcaemia and raised serum alkaline phosphatase) in epileptic patients on longterm treatment with anticonvulsant drugs has been reported several times in the past four years (Schmid, 1967; Kruse, 1968; Dent et al., 1970; Richens and Rowe, 1970; Hunter et al., 1971) .
On average, patients without biochemically manifest osteomalacia have a decreased bone mineral mass (Berger and Munde, 1970; Linde et al., 1971; Christiansen et al., 1972) , and such patients show an increase in bone mineral mass during treatment with vitamin D .
The effect on bone mineral mass of normal persons by small doses of vitamin D is unknown. We report a controlled therapeutic trial on the effect of the treatment in normal subjects and in epileptic patients on anticonvulsants. The bone mineral mass was determined by direct photon absorptiometry on both forearms. Cameron et al. (1968) showed a direct relation between the absorption of photons from 125I and the bone mineral mass. In our modified version of the method (Jensen et al., 1972; Christiansen and R0dbro, 1973) the bone mineral mass is expressed in arbitrary units as a mean value of six scans from each forearm.
The bone mineral mass was measured and termed "initial value"-100% at time to. This measurement was compared in each case with the values in a group of normal subjects (Christiansen and Redbro, 1973) matched for age and sex (see chart).
The epileptic patients and the normal subjects were then allocated at random to two groups. The first group was treated with calcium lactate (390 mg/ca daily) and vitamin D (2,000 IU daily), both drugs given by mouth, and the second group was treated with calcium lactate (390 mg/ca daily) and placebo. Bone mineral mass was measured one month after the treatment was started, t1, and expressed as a percentage of the initial value.
The therapeutic trial was conducted over the months October to November 1972, and Student's t test for pair differences was used to evaluate the effect of treatment. 
Results
The bone mineral mass of the 23 epileptic patients and the 20 normal subjects compared with the values of other normal subjects matched for age and sex are shown in the chart. The initial values of all the 23 epileptic patients were below the corresponding normal mean value. In the group of epileptic patients treated with calcium lactate and vitamin D the mean bone mineral mass rose significantly. In the other three groups the mean bone mineral mass was unchanged (see chart).
Discussion
As previously found, the epileptic patients as a group had subnormal values (Berger and Munde, 1970; Linde et al., 1971; Christiansen et al., 1972) , while the values in the normal subjects scatter around the mean.
This finding, and the unchanged values in both groups of normal subjects and in the placebo groups of epileptic patients, underlines that the method used is well reproducible (Christiansen and R0dbro, 1973) . Our earlier findings , that bone mineral mass rises in epileptics during treatment with a small dose of vitamin D, are confirmed.
In this study we have found a 3% increase in bone mineral mass, while we previously found an increase of nearly 7% . Two factors might contribute to this disparity. Firstly, the initial values of our nine patients were higher than the initial values of the patients in our earlier report. Secondly, the two studies were not planned in the same way, as the patients in the earlier study were treated with calcium lactate for one month before the treatment with vitamin D.
Assuming that bone mineral mass in the forearm is representative of total body calcium (Christiansen and R0dbro 1973) , and that the mean value of normal young men corresponds to 1,000 g of total body calcium , it can be calculated that the mean total body calcium in the epileptic patients on vitamin D rose from 699 to 716 g, corresponding to a mean positive calcium balance of 0 5 g per day during the trial. Introduction Clonidine has found use as an antihypertensive agent in moderate (Smet et al., 1969; Parsons and Morledge, 1970) and severe (Raftos, 1969) hypertension, and when side effects such as orthostatic hypotension make adrenergic blocking agents impractical (Hoobler and Sagastume, 1971) . It has a largely central site of action, and in rabbits it has been shown to have a central inhibitory action on adrenal catecholamine release (Shaw et al., 1971) . A dose-related depression of urinary catecholamine levels has been shown in man (Hokfelt et al., 1970) .
Sudden cessation of clonidine has been seen to result in severe rises in blood pressure (Hokfelt et al., 1969 (Hokfelt et al., 1970 Hoobler, 1969 ) and a symptom complex of agitation, insomnia, and palpitations. The cause of the symptoms has been suggested to be a large catecholamine release, and some data after short-term therapy support this view (Hokfelt et al., 1970) . Identification and further study of this phenomenon is reported.
Materials and Methods
Five patients were studied who had a previously well-documented blood pressure overshoot when clonidine (Catapres) 
